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Purpose: Behcet’s disease (BD) is a systemic inflammatory disease presumably caused by an autoimmune response.
Interleukin (IL)-17 has been demonstrated to be involved in the development and maintenance of certain inflammatory
diseases, including BD. This study was designed to investigate the influence of cyclosporine A (CsA) on IL-17 production
by peripheral blood mononuclear cells (PBMCs) from BD patients in vitro and in vivo.
Methods: Fifteen BD patients with active uveitis were involved in this study. Blood samples were taken from these
patients for analysis of IL-17 and interferon (IFN)-γ. Six patients were re-evaluated at 1 and 3 months after treatment with
CsA. The levels of IL-17 and IFN-γ in the supernatants of PBMCs from patients before treatment cultured without or with
CsA at different concentrations were detected by enzyme-linked immunosorbent assay (ELISA). Flow cytometry was
used to evaluate the frequencies of IL-17-producing and IFN-γ-producing T cells and the expression of CD69 on CD4+
or CD8+ T cells before, 1, and 3 months after CsA treatment.
Results: The results showed that significantly higher levels of IL-17 and IFN-γ were observed in active BD patients as
compared with controls. Treatment with CsA could inhibit the production of both cytokines in association with an
amelioration of intraocular inflammation. In vitro, CsA significantly inhibited the production of IL-17 and IFN-γ by
PBMCs activated with anti-CD3 and anti-CD28 antibodies or phorbol 12-myristate,13-acetate and ionomycin in BD
patients with active uveitis. However, CSA did not influence the CD69 expression in CD4+ and CD8+ T cells induced by
phorbol 12-myristate,13-acetate (PMA) ionomycin.
Conclusions: Our findings showed that CsA can significantly inhibit the intraocular inflammation of BD patients and the
expression of IL-17 and IFN-γ in vivo and in vitro. The results suggested that the inhibitory effect of CsA on uveitis in
BD patients may be partially mediated through inhibiting the production of IL-17 and IFN-γ.
Recent studies have found a new subset of CD4+ T helper
(Th) cells that selectively produce interleukin (IL)-17 and play
a critical role in the pathogenesis of autoimmune and chronic
inflammatory  disorders  [1].  IL-17  is  a  17-kDa  protein,
secreted as a disulfide-linked homodimeric glycoprotein, and
is a member of the IL-17 family [2]. Several reports have
shown that IL-17 stimulates the induction of various pro-
inflammatory cytokines and chemokines [3,4]. Accumulating
evidence suggests that several inflammatory and autoimmune
diseases in human and mouse, such as rheumatoid arthritis,
multiple sclerosis, Crohn’s disease, psoriasis, and uveitis, are
associated with IL-17 overexpression and production [5-10].
Behcet’s disease (BD) is a chronic, systemic, relapsing
inflammatory  disease  mainly  showing  as  four  major
manifestations: recurrent uveitis, oral aphthae, genital ulcers,
or skin lesions [11]. Although various etiologies have been
presumed, BD is believed to be an autoimmune disease in
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origin  [12-14].  Our  recent  study  showed  that  IL-17  was
upregulated in BD patients with active uveitis as compared
with BD patients with inactive uveitis and healthy individuals
[10].
Cyclosporine A (CsA) has been shown to be effective in
reducing  the  frequency  and  severity  of  BD,  especially
intraocular inflammation [15]. It has been demonstrated that
CsA could inhibit the production of several inflammatory
cytokines, such as IL-12, IL-18, and tumor necrosis factor-α
[16,17]. Several reports have shown that CsA could inhibit
IL-17 production in certain autoimmune diseases, such as
Vogt-Koyanagi-Harada (VKH) syndrome [18-20]. It remains
unclear whether CsA can also exert its function via inhibiting
IL-17 production in BD. The purpose of this study was to
investigate the effect of CsA on the expression of IL-17 in BD,
in  vivo  and  in  vitro.  The  results  showed  an  increased
production of IL-17 and interferon-γ (IFN-γ) by peripheral
blood mononuclear cells (PBMCs) in BD patients with active
uveitis. In vitro and in vivo experiments revealed that CsA
significantly downregulated both IL-17 and IFN-γ expression
in active BD patients. These results suggest that CsA may
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880inhibit the intraocular inflammation of BD, presumably by
suppressing both IL-17 and IFN-γ production.
METHODS
Patients: Fifteen BD patients with active uveitis (nine men
and six women), with an average age of 36 years, and 14
healthy  individuals  (nine  men  and  five  women),  with  an
average age of 35 years, were included in this study. All study
subjects were recruited from Zhongshan Ophthalmic Center,
Sun Yatsen University (Guangzhou, P.R. China) from April
2007 to January 2009. The diagnosis of BD disease was based
on the diagnostic criteria designed by the International Study
Group for BD disease. In brief, the diagnostic criteria include
the  presence  of  recurrent  oral  ulceration  plus  two  of  the
following: recurrent genital ulceration, eye lesion (anterior or
posterior  uveitis),  or  skin  lesions  (erythema  nodosum,
pseudofolliculitis or papulopustular lesions) [21]. All of these
BD  patients  showed  active  recurrent  intraocular
inflammation, evidenced by keratic precipitates (100%), flare
and  cells  in  the  anterior  chamber  (100%),  vitreous  cells
(46.7%),  and  retinal  vasculitis,  observed  clinically  or
disclosed  by  fluorescein  angiography  (100%).  The
extraocular  manifestations  were  recurrent  oral  aphthous
lesions (100%), multiform skin lesions (66.7%), recurrent
genital ulcers (44.4%), and arthritis (33.3%). Six out of these
15  patients  had  been  intermittently  treated  with
corticosteroids  for  at  least  1  year  before  coming  to  the
Zhongshan  Ophthalmic  Center,  Guangzhou,  P.R.  China.
However, these patients responded poorly to steroid therapy.
All of the 16 patients did not use immunosuppressive agents
for at least 1 week before visiting us. Blood samples were
collected by veinpuncture from all of the 15 patients before in
vitro  and  in  vivo  treatment  and  normal  controls.  The
heparinized  tubes,  containing  blood  samples,  were
immediately transferred to the laboratory, and then PBMCs
were isolated from blood samples by Ficoll–Hypaque density-
gradient  centrifugation  to  be  subjected  to  the  following
experiments. After blood sampling, CsA (3.0–5.0 mg/kg per
day) in combination with oral prednisone (15–20 mg/day) was
used for the aforementioned six patients. These six patients
were  re-evaluated  at  1  and  3  months  after  CsA  in  vivo
treatment.  The  experimental  design  is  described  below  in
detail. The ocular manifestations of the six patients before and
after treatment with CsA are summarized in Table 1. Fourteen
age- and sex-matched, untreated, healthy individuals, without
ophthalmic  diseases,  were  included  as  control  group.  All
patients and healthy controls showed no associated systemic
abnormalities, and had normal psychomotor development at
the time of collecting blood samples. All procedures followed
the tenets of the Declaration of Helsinki, and informed consent
was obtained from all patients and normal controls.
Measurement of cytokines by enzyme-linked immunosorbent
assay: PBMCs were stimulated with or without anti-CD3
(5  µg/ml;  eBioscience,  San  Diego,  CA)  and  anti-CD28
antibodies (1 µg/ml; eBioscience) for 72 h for determination
of IL-17 and IFN-γ production in BD patients before and after
CsA  treatment.  The  supernatants  were  then  collected  for
analysis.  IL-17  and  IFN-γ  levels  were  detected  using  the
Duoset  enzyme-linked  immunosorbent  assay  (ELISA)
Development  kit  (Research  and  Diagnostics  System,
Minneapolis, MN), with a detection limit of 15 pg/ml. To
determine the effect of CsA on the production of IL-17 and
IFN-γ production in vitro, different concentrations of CsA
(0.4, 2, 10, 50, and 100 ng/ml; Novartis, Switzerland) were
added to cultured PBMCs stimulated with anti-CD3 and anti-
CD28 antibodies for 72 h.
Intracellular cytokine staining: PBMCs were stimulated with
20 ng/ml PMA and 1 μg/ml ionomycin (Sigma-Aldrich, St.
Louis, MO) for 6 h to detect the frequencies of IL-17 and IFN-
γ-producing  T  cells  in  BD  patients  before  and  after  CsA
treatment.  Brefeldin  A  (10  μg/ml;  Sigma)  was  added  to
cultured PBMCs for 4 h. The stimulated PBMCs were washed
in  phosphate  buffered  saline  (137  mM  sodium  chloride,
2.7  mM  potassium  chloride,  10  mM  disodium  hydrogen
phosphate, 2 mM potassium dihydrogen phosphate, pH 7.4)
and incubated with phycoerythrin (PE)-cy7-labeled anti-CD8
(eBioscience) and fluorescein isothiocyanate- labeled anti-
CD69 (eBioscience) or matched isotype (eBioscience) for 30
min in the dark at 4 °C . These PBMCs were fixed in 4%
formaldehyde, permeabilized with 0.1% saponin (Sigma), and
TABLE 1. OCULAR MANIFESTATIONS OF BD PATIENTS BEFORE AND AFTER CSA TREATMENT.
  KPs           Aqueous cells                        Aqueous flare                      Vitreous cells
Patient number 0 1 301 3 0 1 3 0 1 3
1 +++ ++ ± +++ ++ + +++ ++ + ++ + ±
2 +++ + − ++ + − +++ + + − − −
3 +++ ++ − ++ + − ++ + − − − −
4 ++ + − ++ + − ++ + − + ± −
5 +++ ++ ± +++ +±+++ ++ ± ++ + +
6 ++ + + ++ + − ++ + − − − −
In the second row, the “0” indicates before CsA treatment, the “1” indicates after 1-month CsA treatment, and the “3” indicates
after 3-month CsA treatment.
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881stained with Percp-labeled anti-CD3 (BD PharMingen, San
Diego, CA), PE-labeled anti-IL-17 (eBioscience), PE-labeled
anti-IFN-γ (eBioscience), or matched isotype control mAb
(eBioscience). Cells were analyzed using a FACS Calibur and
CellQuest software (Becton Dickinson Biosciences, San Jose ,
CA).
For  determination  of  the  influence  of  CsA  on  the
production of cytokines in vitro, PBMCs were stimulated with
phorbol 12-myristate,13-acetate (PMA) and ionomycin for 6
h in the presence of 50 ng/ml CsA.
Statistical analysis: Statistical analysis was performed using
the  Student  t  test.  A  level  of  p<0.05  was  considered
statistically significant.
RESULTS
In  vitro  inhibition  of  cyclosporin  A  on  the  production  of
interleukin-17  and  interferon-γ  by  peripheral  blood
mononuclear cells from patients with Behcet’s disease and
normal controls: The production of IL-17 and IFN-γ was
significantly increased upon stimulation with anti-CD3 and
anti-CD28 antibodies both in BD patients (n=15) and normal
controls  (n=14).  Anti-CD3-  and  anti-CD28-stimulated
PBMCs produced a larger amount of IL-17 and IFN-γ in active
BD  patients  compared  to  normal  controls  (both  p<0.001;
Figure 1 and Figure 2). PBMCs isolated from BD patients and
normal controls were stimulated with anti-CD3 and CD28
antibodies in combination with different concentrations of
CsA (0.4, 2, 10, 50, and 100 ng/ml). The results showed that
CsA significantly inhibited IL-17 production by polyclonally
stimulated PBMCs from both BD patients and normal controls
in a dose-dependent manner (p<0.05). IL-17 was completely
blocked by CsA at a concentration as low as 50 ng/ml (Figure
1 and Figure 2).
In  vitro  influence  of  cyclosporin  A  on  interleukin-17  and
interferon-γ production by T cells and on T-cell activation:
Isolated PBMCs from BD patients and normal controls were
stimulated with PMA (20 ng/ml) and ionomycin (1 µg/ml) for
6 h in the presence of CsA (50 ng/ml) to study the regulatory
effect of CsA on IL-17 and IFN-γ production. The results
showed that CsA could significantly lower the frequencies of
IL-17 and IFN-γ in CD4+ and CD8+ T cells from both BD
patients and normal controls (Figure 3). However, CsA did
not influence the expression of CD69 in CD4+ and CD8+ T
cells induced by PMA and ionomycin (Figure 4A,B).
The  influence  of  cyclosporin  A  on  the  production  of
interleukin-17  and  interferon-γ  by  peripheral  blood
mononuclear cells from patients with Behcet’s disease in vivo:
The  aforementioned  study  demonstrated  that  CsA  could
significantly suppress IL-17 and IFN-γ production by PBMCs
in vitro. To detect the effect of CsA on IL-17 and IFN-γ
production in vivo, six BD patients with active uveitis were
treated by CsA and re-examined for these cytokines at 1 and
3 months after treatment. At 1 month after treatment with CsA,
the  intraocular  inflammation  in  these  six  patients  was
markedly inhibited. A 3-month treatment with CsA almost
completely  and  clinically  resolved  the  intraocular
inflammation in these patients. Both FACS and ELISA results
showed  that  IL-17  production  by  stimulated  PBMCs  was
significantly decreased after a 1-month treatment (p<0.001,
p=0.006, respectively) and 3-month treatment (both p<0.001)
as compared with production before treatment. The IL-17
production by PBMCs after a 3-month treatment was similar
to that in normal controls (Figure 5A,B). The production of
IFN-γ  by  stimulated  PBMCs  was  also  significantly
suppressed in these patients after 1 and 3 months of CsA
treatment  in  the  ELISA  experiment  (p=0.037,  p=0.006,
respectively; Figure 5C). A similar result was observed in the
FACS experiment (both p<0.001; Figure 5D).
DISCUSSION
In this study we investigated the effect of CsA on IL-17 and
IFN-γ production in vitro and in vivo. An in vitro experiment
showed that CsA suppressed the production of IL-17 and IFN-
γ in BD patients with active uveitis. A 3-month treatment with
this medicine significantly inhibited the production of IL-17
and IFN-γ in BD patients in association with amelioration of
the intraocular inflammation. All these findings suggest that
CsA  may  exert  its  regulative  function  possibly  through
suppressing IL-17 and IFN-γ production.
Figure  1.  The  effect  of  cyclosporin  A  on  the  production  of
interleukin-17 in vitro. Isolated peripheral blood mononuclear cells
(1×106 cells/ml) from BD patients with active uveitis and normal
controls were stimulated with anti-CD3 and anti-CD28 antibodies in
the presence of different concentrations of CsA for 72 h. The IL-17
level in the supernatant was detected using ELISA analysis. Data are
the means±SD of triplicate samples.
Molecular Vision 2010; 16:880-886 <http://www.molvis.org/molvis/v16/a98> © 2010 Molecular Vision
882CsA has been shown to be effective in the treatment of
BD and Vogt-Koyanagi-Harada syndrome [22-24]. In both
diseases IL-17 has been considered as one of the important
cytokines.  Our  recent  studies  showed  that  both  CsA  and
corticosteroids exerted a therapeutic role through inhibiting
production of IL-17 in VKH patients and that CsA had a much
stronger inhibitory effect on IL-17 production compared to
corticosteroids [18,24]. In this study, we found an increased
IL-17 expression in association with active uveitis in BD,
although the results did not show that it was directly involved
in this disease. Another purpose of this study was to examine
whether  CsA  could  inhibit  both  BD  activity  and  IL-17
production and whether there was a correlation between this
cytokine and inflammatory activity. The results showed that
CsA significantly suppressed intraocular inflammation at 1
month and almost resolved this inflammation clinically at 3
months following treatment. The IL-17 production by PBMCs
was significantly decreased at 1 month and almost returned to
a  normal  level  at  3  months  following  treatment.  The
coincidence  of  downregulated  expression  of  IL-17  and
decreased  BD  activity  seems  to  suggest  a  causative
relationship between them. The previous unresponsiveness of
these patients to corticosteroids suggests a predominant effect
of  CsA  in  our  treatment  for  BD  activity,  although  both
medicines may have an additive effect on the production of
Figure 2. The effect of cyclosporin A on the production of interferon-
γ in vitro. Isolated peripheral blood mononuclear cells (1×106 cells/
ml) from BD patients with active uveitis and normal controls were
stimulated with anti-CD3 and anti-CD28 antibodies in the presence
of different concentrations of CsA for 72 h. IFN-γ production in the
supernatant was detected using ELISA analysis. Data are the means
±SD of triplicate samples.
IL-17. Additionally, an in vitro experiment showed that CsA
alone could potently inhibit IL-17 production by PBMCs from
BD patients in a dose-dependent manner. More importantly,
it could completely block the IL-17 production at a relatively
low  dose.  This  result  is  consistent  with  that  reported  by
Ziolkowska et al. [19]. They showed that CsA inhibited IL-17
produced by PBMCs stimulated with IL-15 and PMA.
IFN-γ is another important cytokine involved in BD and
VKH syndrome [9,10,25,26]. Both CsA and corticosteroids
have  been  demonstrated  to  downregulate  this  cytokine  in
VKH syndrome. In our study, we also investigated whether
CsA inhibits the production of IFN-γ in BD patients in vivo
and in vitro. The results also showed that CsA significantly
inhibited in vitro production of IFN-γ, consistent with those
reported  previously  in  VKH  syndrome  [18,27].  The  CsA
treatment  also  inhibited  the  production  of  IFN-γ  in  BD
patients in association with a striking amelioration of active
intraocular  inflammation.  With  prolonged  treatment  a
stronger inhibition on both IFN-γ production and BD activity
was observed. However, unlike the effect of CsA on IL-17, it
did not entirely block the production of IFN-γ. This result is
similar to that observed in the experiment with PBMCs from
VKH syndrome patients [18]. In an earlier study on VKH
syndrome, we found that CsA could also exert its role through
Figure  3.  The  effect  of  cyclosporin  A  on  the  percentages  of
interleukin-17-producing and interferon-γ-producing T cells from
patients with Behcet’s disease and normal controls in vitro. Isolated
peripheral blood mononuclear cells (1×106 cells/ml) were stimulated
with  phorbol  12-myristate,13-acetate/ionomycin  for  6  h  in  the
absence or presence of CsA (50 ng/ml). The percentage of both
IL-17-producing and IFN-γ-producing CD4+ or CD8+ T cells was
significantly higher in BD patients than in normal controls and was
significantly reduced in the presence of CsA. Data are expressed as
means±SD.
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whether there are increased IL-17+ IFN-γ+ T cells in BD and
whether CsA could inhibit this population of T cells in this
disease. More studies are needed to address these issues.
It  is  interesting  to  note  a  protective  role  of  IL-17  in
experimental autoimmune uveitis (EAU), a well-described
counterpart in animals for human uveitis [28]. This result
seems  to  be  in  conflict  with  that  observed  in  human
autoimmune  diseases.  The  discrepancy  between  human
diseases and animal models is not completely understood.
Studies  on  this  difference  may  greatly  contribute  to  our
understanding about BD physiologically and pathologically.
It has been reported that γδ T cells are a potent source of IL-17
[29] and are involved in the development of EAU [30]. It is
Figure 4. The effect of cyclosporin A on T- cell activation at a
concentration of 50 ng/ml. Isolated peripheral blood mononuclear
cells  (1×106  cells/ml)  from  normal  controls  and  patients  with
Behcet’s disease were stimulated with PMA/ionomycin for 6 h in the
presence of CsA (50 ng/ml). Cells were analyzed using FACS. The
expression of CD69 by CD4+ and CD8+ T cells from (A) normal
controls and (B) BD patients was not inhibited by CsA (50 ng/ml).
Data are shown representative of five independent experiments.
not yet clear whether this cell population plays a role in BD.
Figure  5.  The  production  of  interleukin-17  and  interferon-γ  by
polyclonally stimulated peripheral blood mononuclear cells from
patients with Behcet’s disease before and after one- and three- month
cyclosporin A treatment. A: Levels of IL -17 in supernatants of
peripheral blood mononuclear cells from BD patients (n=6) before
and after treatment and normal controls (n=6) were determined by
ELISA.  IL-17  production  by  PBMCs  was  significantly
downregulated in BD patients after CsA treatment compared with
that before treatment. B: The frequency of IL-17-producing T cells
from BD patients before and after treatment and normal controls was
determined by FACS. Both IL-17-producing CD4+ and CD8+ T cells
were significantly decreased in BD patients at 1 and 3 months after
CsA  treatment  compared  with  those  before  treatment.  C:
Concentrations of IFN-γ in supernatants of PBMCs from BD patients
before and after treatment and normal controls were determined by
ELISA. IFN-γ production by polyclonally stimulated PBMCs was
significantly lower in BD patients after CsA treatment than before
treatment. D: The frequency of IFN-γ-producing T cells from BD
patients  before  and  after  treatment  and  normal  controls  were
determined by FACS. Both IFN-γ-producing CD4+ and CD8+ T cells
were significantly decreased in BD patients after CsA treatment
compared with those before treatment. Data are shown representative
of five independent experiments.
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CD69 is a T-cell-surface activation marker and has been
shown to be increased in expression in BD [10,31]. It is not
yet known whether CsA inhibits this molecular marker in BD.
One of our aims was to address whether CsA could influence
its expression in this disease. It is interesting to note that CsA
did not influence CD69 expression at a concentration of 50
ng/ml in vitro using PMA/ionomycin as stimulators. This
result is consistent with that reported earlier by Ortiz et al.
[32] who found that CsA did not influence CD69 expression
induced by PMA and TNF-α but decreased the expression of
CD69 induced by IL-15 and a calcium ionophore. Further
study is needed to clarify the influence of CsA on CD69
expression induced by these two stimulators in BD disease.
In  conclusion,  our  study  showed  that  CsA  could
completely  block  the  in  vitro  production  of  IL-17  and
significantly decrease the production of IFN-γ. A 3-month
treatment  of  CsA  greatly  ameliorated  the  intraocular
inflammation  of  BD  patients  in  association  with
downregulated expression of IL-17 and IFN-γ. Together with
our previous study on VKH disease, these results seem to
suggest that CsA may exerts its therapeutic effect on BD
possibly through inhibiting IL-17 and IFN-γ and that it may
be universally used for the treatment of diseases mediated by
IL-17 as well as IFN-γ. On the other hand, it is not clear if
other medicines or agents used for the treatment of BD as well
as other autoimmune diseases, for instance inflixmab and
IFN-α, have effects similar to CsA. More studies are needed
to clarify these issues.
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